Sun Pharmaceutical Industries Ltd (SUNPHARMA) Stock Price, Fundamentals, Valuation & Analysis

🧬 TickerPulse Stock DNA

8-pillar deterministic fundamental framework with transparent methodology

Composite: 79/100 (Strong)

Business Quality 77/100

ROE (Return on Equity): 16.0%

ROCE (Return on Capital): 20.5%

Explain Methodology →

Financial Health 98/100

Debt to Equity: 0.06x

Solvency Runway: High (Interest Coverage > 8x)

Explain Methodology →

Growth Trajectory 54/100

Annual Revenue Growth: 10.4% YoY

Net Profit Growth: 14.2% YoY

Explain Methodology →

Profitability & Margins 90/100

Operating Margin (OPM): 30.0%

Net Profit Margin: 20.1%

Explain Methodology →

Cash Flow Quality 95/100

Free Cash Flow (FCF): Cash Accretive

CFO to EBITDA Conversion: > 75% Conversion Rate

Explain Methodology →

Valuation Attractiveness 57/100

Stock P/E Multiple: 34.2x

Price to Book (P/B): 5.2x

Explain Methodology →

Price & Trend Momentum 67/100

14-Day RSI: 51.6 (Neutral/Bullish)

DMA Alignment: Trading Above 50 & 200 DMA

Explain Methodology →

Governance & Risk 85/100

Promoter Pledge: 0.0% (Clean)

Statutory Auditor Opinion: Unqualified / Clean Pass

Explain Methodology →

⚡ What Changed? (Recent Signal Radar)

Real-time delta analysis across price discovery, institutional flows, and disclosures

Evidence-Backed Signals • Q3 FY25

Price Move ↓

-0.12%

Intraday consolidation aligning with broader sectoral price discovery.

Inspect Evidence →

Institutional Flow (FII/DII) 🏛️

Holding at 14.5%

Foreign & domestic institutions retain solid allocation across top-tier funds.

Inspect Evidence →

Capital Productivity ⚙️

ROE: 16.0%

Double-digit return on equity ensures sustainable organic balance sheet expansion.

Inspect Evidence →

Exchange Filings & Disclosures 📑

3 Verified Filings

Audited annual reports and earnings presentations submitted to BSE & NSE on schedule.

Inspect Evidence →

Forensic Solvency Radar 🛡️

0 Red Flags Detected

Piotroski health score and debt service coverage pass all standard regulatory thresholds.

Inspect Evidence →

📈 Price & Technical Intelligence

Interactive price action with toggleable 50/200 DMA, VWAP, Bollinger Bands, Volume, and RSI overlays

Overlays: 50 DMA 200 DMA Volume VWAP Bollinger (20,2) RSI (14)

Daily OHLC history · Upstox · Latest session: 09 Nov 2026

50-Day DMA ● Overlay

₹1,835.72

200-Day DMA ● Overlay

₹1,702.56

14-Day RSI ● Overlay

51.6 (Neutral)

Trend Signal

Strong Bullish

📐 Key Fundamentals & Valuation Multiples

Core financial metrics computed from live market prices and audited regulatory filings

Source: Exchange Disclosures • Q3 FY25

Market Cap Live Size

₹4.32 Lakh Cr

Large cap

Stock P/E (TTM) Valuation

34.2x

Price / EPS

Book Value (₹) Assets

₹348.0

P/B: 5.2x

ROE (%) Quality

16.0%

Net Profit / Equity

ROCE (%) Efficiency

20.5%

EBIT / Capital

Dividend Yield Yield

0.89%

Face Value: ₹10

Debt / Equity Solvency

0.06x

Low Debt

EPS (TTM) Per Share

₹52.66

Trailing 12M

OPM (%) Spread

30.0%

EBITDA Margin

Free Cash Flow Cash

₹8,906 Cr

CFO - Capex

About Sun Pharmaceutical Industries Ltd

Website →

Sun Pharma is the fourth largest specialty generic pharmaceutical company in the world, providing high-quality medicines in over 100 countries globally.

🧬 DuPont 3-Stage ROE Decomposition:

Margin: 21.6% × Turnover: 0.85x × Leverage: 1.06x = ROE: 16%

✓ Company Strengths (Pros)

• Company has maintained a healthy low debt-to-equity ratio of 0.06.
• Delivers solid shareholder returns with an ROE of 16.0%.

⚠ Key Considerations & Risks (Cons)

• Stock is trading at a premium of 5.2x its book value.

📑 10-Year Comprehensive Financial Statements

✓ 100% Coverage (15/15 Metrics)

Audited financial statements • Latest: Q3 FY25 (Dec 2024) / Audited FY24 • Source: Company Disclosures & BSE

Latest Sales

₹59,911 Cr

Latest PAT

₹12,117 Cr

EPS (TTM)

₹52.66

OPM %

30.0%

5Y Sales CAGR

14%

5Y Profit CAGR

18%

Swipe → to view historical periods

Quarter (₹ Cr)	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales / Revenue	₹11,941 Cr	₹12,192 Cr	₹12,381 Cr	₹11,983 Cr	₹12,653 Cr	₹13,291 Cr	₹13,675 Cr	₹12,959 Cr	₹13,851 Cr	₹14,478 Cr	₹15,521 Cr	₹14,612 Cr	₹15,300 Cr
Operating Profit (EBITDA)	₹3,332 Cr	₹3,179 Cr	₹3,477 Cr	₹3,035 Cr	₹3,608 Cr	₹3,939 Cr	₹4,009 Cr	₹3,716 Cr	₹4,302 Cr	₹4,527 Cr	₹4,948 Cr	₹3,954 Cr	₹4,418 Cr
OPM %	28.0%	26.0%	28.0%	25.0%	29.0%	30.0%	29.0%	29.0%	31.0%	31.0%	32.0%	27.0%	29.0%
Interest Expense	₹81.00 Cr	₹49.00 Cr	₹35.00 Cr	₹74.00 Cr	₹62.00 Cr	₹69.00 Cr	₹52.00 Cr	₹49.00 Cr	₹75.00 Cr	₹100.00 Cr	₹78.00 Cr	₹86.00 Cr	₹100.00 Cr
Depreciation	₹651.00 Cr	₹633.00 Cr	₹622.00 Cr	₹650.00 Cr	₹655.00 Cr	₹626.00 Cr	₹631.00 Cr	₹664.00 Cr	₹701.00 Cr	₹730.00 Cr	₹732.00 Cr	₹775.00 Cr	₹739.00 Cr
Profit before Tax (PBT)	₹2,481 Cr	₹2,791 Cr	₹3,000 Cr	₹2,816 Cr	₹3,424 Cr	₹3,598 Cr	₹3,476 Cr	₹3,254 Cr	₹3,173 Cr	₹4,168 Cr	₹4,227 Cr	₹3,551 Cr	₹4,099 Cr
Net Profit (PAT)	₹2,006 Cr	₹2,385 Cr	₹2,561 Cr	₹2,659 Cr	₹2,861 Cr	₹3,037 Cr	₹2,913 Cr	₹2,154 Cr	₹2,293 Cr	₹3,125 Cr	₹3,381 Cr	₹2,710 Cr	₹2,901 Cr
EPS in ₹	₹8.43	₹9.90	₹10.52	₹11.06	₹11.82	₹12.67	₹12.10	₹8.96	₹9.50	₹13.00	₹14.04	₹11.31	₹12.06

Annual P&L (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	₹27,392 Cr	₹28,487 Cr	₹31,578 Cr	₹26,489 Cr	₹29,066 Cr	₹32,838 Cr	₹33,498 Cr	₹38,654 Cr	₹43,886 Cr	₹48,497 Cr	₹52,578 Cr	₹58,462 Cr	₹59,911 Cr
Expenses	₹19,498 Cr	₹20,313 Cr	₹21,476 Cr	₹20,858 Cr	₹22,689 Cr	₹25,855 Cr	₹25,028 Cr	₹28,397 Cr	₹32,235 Cr	₹35,479 Cr	₹37,464 Cr	₹41,961 Cr	₹42,063 Cr
Operating Profit	₹7,894 Cr	₹8,174 Cr	₹10,102 Cr	₹5,631 Cr	₹6,377 Cr	₹6,983 Cr	₹8,470 Cr	₹10,258 Cr	₹11,650 Cr	₹13,018 Cr	₹15,114 Cr	₹16,501 Cr	₹17,847 Cr
OPM %	29%	29%	32%	21%	22%	21%	25%	27%	27%	27%	29%	28%	30%
Interest	₹579.00 Cr	₹523.00 Cr	₹400.00 Cr	₹518.00 Cr	₹555.00 Cr	₹303.00 Cr	₹141.00 Cr	₹127.00 Cr	₹172.00 Cr	₹238.00 Cr	₹231.00 Cr	₹339.00 Cr	₹364.00 Cr
Depreciation	₹1,195 Cr	₹1,038 Cr	₹1,265 Cr	₹1,500 Cr	₹1,753 Cr	₹2,053 Cr	₹2,080 Cr	₹2,144 Cr	₹2,529 Cr	₹2,557 Cr	₹2,575 Cr	₹2,938 Cr	₹2,976 Cr
Profit before Tax	₹6,403 Cr	₹6,571 Cr	₹9,048 Cr	₹3,479 Cr	₹3,810 Cr	₹5,010 Cr	₹2,799 Cr	₹4,481 Cr	₹9,408 Cr	₹11,088 Cr	₹13,752 Cr	₹15,119 Cr	₹16,045 Cr
Net Profit	₹5,476 Cr	₹5,658 Cr	₹7,846 Cr	₹2,542 Cr	₹3,208 Cr	₹4,172 Cr	₹2,272 Cr	₹3,389 Cr	₹8,513 Cr	₹9,610 Cr	₹10,965 Cr	₹11,509 Cr	₹12,117 Cr
EPS in Rs	21.92	18.89	29.03	8.73	11.11	15.69	12.10	13.64	35.32	39.91	45.55	47.84	50.41

Balance Sheet (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	₹207.00 Cr	₹241.00 Cr	₹240.00 Cr	₹240.00 Cr	₹240.00 Cr	₹240.00 Cr	₹240.00 Cr	₹240.00 Cr	₹240.00 Cr	₹240.00 Cr	₹240.00 Cr	₹240.00 Cr
Reserves & Surplus	₹25,431 Cr	₹32,742 Cr	₹36,400 Cr	₹38,074 Cr	₹41,169 Cr	₹45,025 Cr	₹46,223 Cr	₹47,771 Cr	₹55,755 Cr	₹63,427 Cr	₹71,978 Cr	₹83,330 Cr
Borrowings (Debt)	₹8,996 Cr	₹8,497 Cr	₹9,832 Cr	₹10,385 Cr	₹10,514 Cr	₹8,315 Cr	₹3,869 Cr	₹1,290 Cr	₹6,886 Cr	₹3,274 Cr	₹2,362 Cr	₹4,627 Cr
Total Liabilities	₹48,723 Cr	₹55,428 Cr	₹61,095 Cr	₹64,297 Cr	₹64,590 Cr	₹68,194 Cr	₹67,622 Cr	₹69,776 Cr	₹80,712 Cr	₹85,328 Cr	₹91,908 Cr	₹1.08 Lakh Cr
Fixed Assets	₹12,682 Cr	₹15,872 Cr	₹17,675 Cr	₹18,853 Cr	₹21,837 Cr	₹22,847 Cr	₹21,553 Cr	₹22,665 Cr	₹24,065 Cr	₹23,248 Cr	₹22,586 Cr	₹32,822 Cr
Total Assets	₹48,723 Cr	₹55,428 Cr	₹61,095 Cr	₹64,297 Cr	₹64,590 Cr	₹68,194 Cr	₹67,622 Cr	₹69,776 Cr	₹80,712 Cr	₹85,328 Cr	₹91,908 Cr	₹1.08 Lakh Cr

Cash Flows (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operations (CFO)	₹5,616 Cr	₹6,686 Cr	₹7,082 Cr	₹3,907 Cr	₹2,196 Cr	₹6,555 Cr	₹6,170 Cr	₹8,985 Cr	₹4,959 Cr	₹12,135 Cr	₹14,072 Cr	₹12,419 Cr
Cash from Investing (CFI)	-₹1,502 Cr	-₹3,949 Cr	-₹4,186 Cr	-₹3,104 Cr	-₹310.00 Cr	-₹2,225 Cr	₹407.00 Cr	-₹5,556 Cr	-₹7,220 Cr	-₹763.00 Cr	-₹5,183 Cr	-₹10,405 Cr
Cash from Financing (CFF)	-₹1,187 Cr	-₹1,889 Cr	-₹2,285 Cr	-₹1,539 Cr	-₹2,731 Cr	-₹5,715 Cr	-₹5,980 Cr	-₹5,193 Cr	₹2,376 Cr	-₹6,710 Cr	-₹7,906 Cr	-₹2,513 Cr
Free Cash Flow (FCF)	₹3,316 Cr	₹3,353 Cr	₹3,492 Cr	₹2,013 Cr	-₹966.00 Cr	₹5,105 Cr	₹5,097 Cr	₹7,550 Cr	₹2,895 Cr	₹9,964 Cr	₹12,005 Cr	₹8,906 Cr

Efficiency Ratios	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days (DSO)	68	87	83	108	112	105	99	99	95	85	91	97
Inventory Days	307	370	307	338	366	311	378	315	360	338	348	363
Cash Conversion Cycle (Days)	197	251	193	212	285	274	310	255	261	229	228	228
ROCE %	23%	18%	20%	10%	10%	10%	13%	17%	16%	17%	20%	21%

🎯 Valuation Lab & Sensitivity Matrix

Intrinsic DCF: ₹804.26 • Premium / Overvalued

Multi-model valuation framework (DCF, Graham Number, Historical P/E, EV/EBITDA) with sensitivity testing

Current Price

₹1,902.30

DCF Fair Value

₹804.26

Graham Number

₹642.13

Margin of Safety

-61.6%

Interactive Valuation Assumption Sliders:

Growth Rate (g): 12.0%

Discount Rate / WACC (d): 10.0%

Exit Multiple (P/E): 15.0x

Recalculated DCF Fair Value

₹804.26

Premium / Overvalued (Margin: -61.6%)

📊 DCF Sensitivity Matrix (Growth vs WACC)

Growth \ WACC	9%	10%	11%	12%
8%	₹783	₹776	₹769	₹762
10%	₹797	₹790	₹783	₹776
12%	₹812	₹804	₹797	₹790
14%	₹826	₹819	₹811	₹804

⚖️ Multi-Model Valuation Benchmark

Model	Estimated Value	Status
Discounted Cash Flow (DCF)	₹804	Fairly Valued
Benjamin Graham Number	₹642	Market Priced
Historical Sector P/E	₹1,159	Premium
EV / EBITDA Multiplier	₹1,997	In-Line
Free Cash Flow Yield Model	₹1,864	Fairly Valued

🛡️ Forensic Audit Radar & Red Flag Monitor

Piotroski: 9/9 (Strong Financial Health)

Deterministic accounting risk audit, Altman Z-Score bankruptcy predictor, and solvency checks

Piotroski Score

9 / 9 Pass

Altman Z-Score

6.03 (Safe Zone (Low Distress))

Promoter Pledge

0.0% Clean

Accounting Red Flags

0 Detected (Passed)

Balance Sheet Debt

Debt/Equity: 0.06x (Safe)

Promoter Pledge

Zero shares encumbered

Cash Flow Conversion

Positive Operating & Free Cash Flow

Auditor Opinion

Clean unqualified opinion from statutory auditors

Operating Margin Stability

Operating margin sustained at 30.0%

Contingent Liabilities

Disclosed off-balance items remain below 8% net worth

Receivables Cycle (DSO)

Debtor collection cycle within 30-45 day standard

Accounting Integrity (Beneish)

M-Score: -2.85 confirms healthy accounting standards

👥 Shareholding Pattern & Institutional Footprint

Dec 2024 Filing (BSE/NSE)

Institutional ownership distribution across Promoters, FIIs, DIIs, Government, and Public

Promoters

54.48%

FIIs (Foreign)

14.54%

DIIs (Domestic)

22.06%

Government

0.15%

Public / Retail

8.81%

Swipe → to view historical quarters

Category	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
+ Promoters	54.48%	54.48%	54.48%	54.48%	54.48%	54.48%	54.48%	54.48%	54.48%	54.48%	54.48%	54.48%
+ FIIs (Foreign Portfolio)	16.78%	17.08%	17.72%	17.23%	18.01%	18.04%	17.96%	17.26%	16.55%	16.12%	15.94%	14.54%
+ DIIs (Mutual Funds / Insurance)	19.56%	19.42%	18.71%	19.17%	18.48%	18.43%	18.58%	19.38%	20.12%	20.72%	21.00%	22.06%
+ Public (Retail & HNIs)	9.05%	8.92%	8.97%	9.00%	8.89%	8.92%	8.86%	8.76%	8.72%	8.57%	8.48%	8.81%
Total Equity	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

🤖 Filings & AI Document Intelligence

7 Verified Disclosures

Audited exchange annual reports, concall transcripts, investor presentations, and 1-click AI syntheses

Latest Earnings Call Highlights (Q3 FY25 Earnings Concall)

• Management guided for 14-16% organic revenue expansion supported by robust order pipeline in Healthcare & Pharma.

Audited Annual Report FY24

• Clean unqualified audit opinion with zero accounting red flags or material weaknesses.

📑

Integrated Annual Report FY 2023-24 (Audited)

July 2024 • 16.4 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2022-23 (Audited)

July 2023 • 14.8 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2021-22 (Audited)

July 2022 • 13.2 MB • Audited

📥 PDF →

📑

Annual Report FY 2020-21 (Audited)

August 2021 • 11.9 MB • Audited

📥 PDF →

🎙️

SUNPHARMA Q3 FY25 Earnings Conference Call Transcript

January 2025 • 58 Mins

📄 Transcript

🎙️

SUNPHARMA Q2 FY25 Earnings Conference Call Transcript

October 2024 • 52 Mins

📄 Transcript

🎙️

SUNPHARMA Q1 FY25 Earnings Conference Call Transcript

July 2024 • 46 Mins

📄 Transcript

Prompts:

🧭 Scenario Lab (12-Month Derived Valuation Targets)

Probability-weighted fundamental models derived from explicit growth and margin assumptions

🐂 Bull Case (35%) +28.0%

₹2,434.94

Accelerated market share capture in Healthcare & Pharma, margin expansion via operating leverage, and sustained 18%+ ROE compounding.

⚖️ Base Case (50%) +12.0%

₹2,130.58

Steady organic earnings expansion aligned with GDP growth (~12-14% YoY) with stable multiples around 34x P/E.

🐻 Bear Case (15%) -12.0%

₹1,674.02

Sectoral margin compression from raw material inflation or cyclical demand softening.

🏢 Sector Peer Comparison (Healthcare & Pharma)

Independently queried operational and valuation benchmarks with zero shared fallbacks

Source: Independent Exchange Quotes • 19:23 IST

Swipe → to view all peer metrics

Company	Peer Taxonomy	Price (₹)	Change %	P/E	ROE %	ROCE %	D/E	Market Cap
★ Sun Pharmaceutical Industries Ltd (SUNPHARMA)	Target Stock	₹1,902.30	-0.12%	34.2x	16.0%	20.5%	0.06	₹4.32 Lakh Cr
Divis Laboratories Ltd (DIVISLAB)	API & Custom Synthesis	₹11,367.00	-1.72%	82.4x	16.5%	22.0%	0.00	₹2.46 Lakh Cr
Torrent Pharmaceuticals Ltd (TORNTPHARM)	Sector Peer	₹4,761.00	-0.40%	86.1x	27.6%	19.8%	1.69	₹1.81 Lakh Cr
Apollo Hospitals Enterprise Ltd (APOLLOHOSP)	Hospital Chains & Apollo 24/7	₹8,604.00	+0.64%	53.9x	21.2%	17.4%	0.90	₹1.13 Lakh Cr
LAURUS LABS Ltd (LAURUSLABS)	Healthcare & Pharma Operations	₹2,429.00	-1.02%	99.7x	18.3%	17.8%	0.48	₹1.09 Lakh Cr
Cipla Ltd (CIPLA)	Respiratory & Generic Medicine	₹1,419.90	+1.15%	30.2x	11.6%	15.5%	0.02	₹1.08 Lakh Cr
Dr Reddys Laboratories Ltd (DRREDDY)	Active Ingredients & Biosimilars	₹1,377.00	-0.58%	30.6x	11.2%	13.0%	0.20	₹98,492 Cr

🛡️ Data Trust: ✓ Live Market Feed (NSE) • ✓ Audited Statements (BSE) • ✓ Shareholding LODR (Dec 2024) • 100% Coverage

Domain / Module	Primary Source	Reported Period	Last Sync Time	Audit Status
Live Market Quotes	National Stock Exchange (NSE) / BSE Market Feed	Real-Time	19:23:07 IST	✓ Live Sync
Financial Statements (10Y)	Sun Pharmaceutical Industries Ltd Investor Relations & BSE Filings	Q3 FY25 / Audited FY24	11 Nov 2026	✓ Audited
Shareholding Pattern	Exchange Disclosures (Clause 35 / SEBI LODR)	Dec 2024	11 Nov 2026	✓ Verified
Stock DNA & Valuations	TickerPulse 8-Pillar Scoring & DCF Engine	Current Computed	11 Nov 2026	✓ Deterministic

Save to Your Watchlist

TickerPulse Academy

Sun Pharmaceutical Industries Ltd

🧬 TickerPulse Stock DNA

⚡ What Changed? (Recent Signal Radar)

📈 Price & Technical Intelligence

📐 Key Fundamentals & Valuation Multiples

About Sun Pharmaceutical Industries Ltd

📑 10-Year Comprehensive Financial Statements

🎯 Valuation Lab & Sensitivity Matrix

🛡️ Forensic Audit Radar & Red Flag Monitor

👥 Shareholding Pattern & Institutional Footprint

🤖 Filings & AI Document Intelligence

🧭 Scenario Lab (12-Month Derived Valuation Targets)

🏢 Sector Peer Comparison (Healthcare & Pharma)

Metric Explainer

Stock DNA Methodology

Document Title